956462-75-2

Basic information

• Product Name: [1-(2,3-dioxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-piperidin-4-yl]-carbamic acid tert-butyl ester
• Synonyms: [1-(2,3-dioxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-piperidin-4-yl]-carbamic acid tert-butyl ester
• CAS NO: 956462-75-2
• Molecular Weight: 346.386
• Mol File: 956462-75-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: [1-(2,3-dioxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-piperidin-4-yl]-carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [1-(2,3-dioxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-piperidin-4-yl]-carbamic acid tert-butyl ester(956462-75-2)
• EPA Substance Registry System: [1-(2,3-dioxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-piperidin-4-yl]-carbamic acid tert-butyl ester(956462-75-2)

Safety Data

• Hazardous Substances Data: 956462-75-2(Hazardous Substances Data)

Upstream product

• 346599-62-0 4-chloro-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 55052-28-3 4-chloro-7-azaindole 

Relevant articles and documents

PHARMACEUTICAL COMPOUNDS

Compounds of the formula (I), and salts, solvates, tautomers and N-oxide thereof; wherein TG is selected from groups (1) and (2): wherein the asterisk (*) represents the point of attachment of the group E to the group X; Rla is an optionally substituted aryl or heteroaryl group; Rlb is hydrogen or a group Rla; X is an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 are heteroatoms selected from O, N and S; and A, E, R2, R3, R4, Q1 and Q2 are as defined in the claims; provided that when E is aryl or heteroaryl, then Q2 is other than a bond; and further provided that the moiety (a) is other than a group (BG1) or (BG2); wherein (BGl) and (BG2) are each optionally substituted; T is N or CRZ; J1-J2 is selected from N=C(RZ), (RZ)C=N, (RZ)N-C(O), (RZ)2C-C(O), N=N and (RZ)C=C(R6); J4 -J3 is a group N=C(RZ) or a group (RZ)N-CO; and RZ is hydrogen or a substituent. The compounds of the formula (I) have PKA and PKB kinase inhibiting activity and are useful in the treatment of cancers.